Indication CINRYZE® (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).
For eligible patients ages 6+ prescribed a Takeda HAE therapy.
Takeda's OnePath program helps patients navigate insurance access and coverage issues. Patient Support Managers can help your patients understand their coverage for CINRYZE and provide information about financial assistance options.
OnePath Co-Pay Assistance Program*
OnePath understands that costs associated with treatment can act as a barrier to patient access. The OnePath Co-pay Assistance Program helps eligible insured patients cover certain out-of-pocket treatment costs. This program will also cover certain infusion expenses for eligible patients, up to the program maximum, regardless of financial status.*
*IMPORTANT NOTICE: The OnePath Co-Pay Assistance Program (the Program) is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), or other federal or state programs (including any state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Co-payment assistance under the Program is not transferable. The Program only applies in the United States and does not apply where prohibited by law, taxed, or restricted. Coverage of certain infusion charges does not apply for patients residing in Massachusetts, Michigan, Minnesota, Rhode Island, and Vermont. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice.
Complete the form with your patient and fax it to 1-855-ONEPATH(1-855-663-7284).